Today: 20 March 2026
RELX share price jumps nearly 2% today as investors look ahead to Feb 12 results
5 January 2026
1 min read

RELX share price jumps nearly 2% today as investors look ahead to Feb 12 results

LONDON, Jan 5, 2026, 09:50 GMT — Regular session

  • RELX (REL.L) rose 1.9% in early London trading, snapping a run of weakness that left the stock near its 12-month low.
  • A firmer European tape helped, with investors weighing fresh geopolitical risk and the outlook for rate cuts.
  • The next company catalyst is RELX’s full-year results on Feb. 12.

RELX shares rose 58 pence, or 1.9%, to 3,041 pence by 09:29 GMT, after trading as high as 3,060 pence. The stock is still down 9.4% over the past 52 weeks and remains about 28% below its 12-month high, Financial Times market data showed.  FT Markets

The bounce matters because RELX is widely held for its steady, subscription-heavy revenues, making it a go-to “defensive” name when investors want earnings visibility. When it moves sharply early in the year, it can signal portfolio repositioning rather than a single company headline.

That repositioning is happening against a noisier backdrop. European stocks traded firmer on Monday as investors bought defence shares after U.S. military action in Venezuela, while technology also led gains and traders watched for clues on how quickly interest-rate cuts might arrive.  Reuters

In London, the FTSE 100 started the session higher, supported by strength in defence-linked names, according to Trading Economics data carried by TradingView.  TradingView

Technically minded investors also watch whether a stock is reclaiming key trend lines after a slide. A “moving average” is a rolling average price used to gauge direction; when a share price moves above it, some traders read it as a sign selling pressure is easing.

Still, the relief rally has company-specific risks waiting in the wings, starting with any shift in global risk appetite. “The removal of Venezuelan President Nicolas Maduro by the U.S. is unlikely to have meaningful near-term economic consequences for the global economy,” Neil Shearing, group chief economist at Capital Economics, said, while warning political and geopolitical repercussions would reverberate.  Reuters

Investors in Europe also had a full macro diary to navigate on Monday, including the euro zone’s January Sentix index and the Bank of England’s consumer credit and mortgage lending figures for November.  Reuters

For RELX, attention turns to Feb. 12, when the company is scheduled to report results for the year to Dec. 31, 2025. Traders will be listening for guidance on underlying growth, margins and cash returns, with any disappointment likely to test support after the recent slide.  Relx

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Halliburton stock rises nearly 5% premarket as Venezuela oil rebuild talk lifts service names
Previous Story

Halliburton stock rises nearly 5% premarket as Venezuela oil rebuild talk lifts service names

GSK share price today: why the stock dipped after China approved Nucala for COPD
Next Story

GSK share price today: why the stock dipped after China approved Nucala for COPD

Go toTop